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Homeodomain, forkhead domain, and paired domain-containing transcription factors play a major role in development, tissue-
speciﬁc gene expression, and tissue homeostasis in organs where they are expressed. Recently, their roles in stem cell and cancer
biology are emerging. In the thyroid, NKX2-1, FOXE1, and PAX8 transcription factors are responsible for thyroid organogenesis
andexpressionofthyroid-speciﬁc genes critical forthyroid hormonesynthesis.In contrastto theirknownroles ingene regulation,
thyroid development and homeostasis, their involvement in stem cell, and/or cancer biology are still elusive. In order to further
understand the nature of thyroid cancer, it is critical to determine their roles in thyroid cancer.
1.Introduction
Tissue-speciﬁc transcription factors play a pivotal role in
regulating expression of tissue-speciﬁc genes, thereby con-
trolling the function, homeostasis, and diﬀerentiation of
tissue where they are expressed. Their altered expression
due to gene mutation, deletion, ampliﬁcation, and/or epi-
genetic modiﬁcation, and/or posttranslational modiﬁcation
can change the cell fate and perturb metabolism and differ-
entiation status, leading to various clinical conditions. Since
both cell proliferation and diﬀerentiation are involved in the
process of normal and cancer development, it is not surpris-
ing that genes critical for development play an important
role in oncogenesis. Transcription factors, containing the
homeobox [1, 2], forkhead domain (FOX) [3], and paired
domain (PAX) [4], that are among those expressed tissue-
specifically that play a critical role in tissue homeostasis and
development, can also have roles in carcinogenesis. Thyroid
is an organ in which the homeodomain, forkhead domain,
and paired domain-containing transcription factors all play
major roles in tissue-speciﬁc gene expression and thyroid
development. The current view on the roles of thyroid-
speciﬁc transcription factors in thyroid cancer will be sum-
marized below.
2.Thyroid-SpeciﬁcTranscriptionFactors
The three distinct thyroid-speciﬁc transcription factors are
critical for the function of thyroid: NKX2-1 (also called
TTF1, TITF1, T/EBP, or NKX2.1) [5, 6], FOXE1 (also called
TTF2 or TITF2) [7], and PAX8 [8]( T a b l e1). They are mem-
bers of the homeodomain, forkhead box, and paired box
family of transcription factors, respectively, and regulate
genes encoding thyroglobulin, thyroid peroxidase, thyrotro-
pin receptor, and sodium/iodide symporter, proteins critical
for thyroid hormone synthesis [5–7, 9–14]. They are also
essential forthyroid development[15–17]; Nkx2-1-null mice
are born withoutthe thyroid (agenesis) [16], while Pax8-null
mice are severely hypothyroidism with rudimental thyroid
remnant [17]. Foxe1-null mice have either agenesis or thy-
roid ectopy [15]. These transcription factors are responsible
for the athyreosis, hypothyroidism, and/or ectopic thyroid,
which provide crucial clues to their roles in thyroid dysgen-
esis in humans [18]. In addition to thyroid, NKX2-1 is
expressed in lung primordium and ventral forebrain [16],
PAX8 in developing kidney [8], and FOXE1 in the ﬂoor of
the foregut and the craniopharyngeal ectoderm including
Rathke’s pouch during development [15]. At later stages,
FOXE1 is expressed in the secondary palate, deﬁnitive2 Journal of Thyroid Research
Table 1: Thyroid-speciﬁc transcription factors and thyroid cancers.
Thyroid
phenotype in
null mice
Gene
requirement
Expression in
thyroid cancer
Common
variants/Gene
mutations for
thyroid cancer
predisposition
Other speciﬁcs
NKX2-1 Athyreosis
Proliferation and
survival of
thyroid follicular
cells and C cells
Level correlates
with the degree of
diﬀerentiation
14q13.3: PTC, FTC Gene mutation increases
thyroid cell proliferation
A339V: PTC
Lineage-speciﬁc
oncogene ampliﬁed in
lung cancer
PAX8
Athyreosis,
rudimental
thyroid
remains
Proliferation and
survival of
thyroid follicular
cells
Correlation
between expression
level and
diﬀerentiation not
clear
PAX8/PPARγ
fusion protein:
FTC
Expression found in
cancers of other tissues
such as kidney,
M¨ ullerian system, and
ovary
FOXE1 Athyreosis or
ectopia
Migration of
thyroid
primordium
Level correlates
with the degree of
diﬀerentiation
rs965513 on
9q22.33: PTC,
FTC,
radiation-induced
PTC
LOH at D9S180 on
9q22.3: frequently found
in skin SCC
rs1867277
(−283G > A): PTC
16 Ala variant:
associated with SCC
PTC: papillary thyroid carcinoma, FTC: follicular thyroid carcinoma, SCC: squamous cell carcinoma, and LOH: loss of heterozygosity.
choanae, whiskers, and hair follicles [19]. Some structures
derived from these areas are also defective in respective null
mice. Thus, Nkx2-1-null mice also have severely hypoplastic
lung, defective hypothalamus, and pituitary agenesis [16].
Foxe1- n u l lm i c eh a v ec l e f tp a l a t e[ 15]. Similar to the defects
found in the Nkx2-1-null mice and sometimes more man-
ifested in humans, various mutations in the NKX2-1 gene
result in the Brain-Thyroid-Lung syndrome, which is char-
acterized by benign hereditary chorea, congenital hypo-
thyroidism, and respiratory diseases [20–22]. Mutations in
the FOXE1 gene are responsible for syndromic congeni-
tal hypothyroidism dysgenesis, cleft plate, and spiky hair
[22–24].
2.1. NKX2-1
2.1.1. NKX2-1 and Cancer. Due to the nature of tissue-
speciﬁc expression, NKX2-1 is expressed in human thyroid
and lung cancers [25–28]. In particular, NKX2-1 is highly
expressed in human lung adenocarcinomas and small cell
carcinomas (∼60–90%) [25, 26, 29]. NKX2-1 has been
widely used as a marker for the diagnosis of primary and
metastatic lung cancer [30] and as a prognostic indicator for
survival [26, 31, 32]. In fact, NKX2-1 is a lineage-speciﬁc
oncogene ampliﬁed in lung cancers and the survival of a
subset of adenocarcinoma cells depends on the sustained
expression of NKX2-1 [33–35]. However, no mutations in
the NKX2-1 gene are described in any adenocarcinomas
examined in these studies. Patients with adenocarcinomas
that lack NKX2-1 expression or have NKX2-1 expression
accompanied by NKX2-1 gene ampliﬁcation tend to have
a signiﬁcantly worse prognosis than patients with NKX2-1
expression and no NKX2-1 gene ampliﬁcation [32].
In contrast to the expression in lung, NKX2-1 is ex-
pressed at lower levels in malignant thyroid as compared to
normal thyroid [36]. The level of expression is signiﬁcantly
correlatedwiththeprogressive dediﬀerentiationandincrease
of malignancy of thyroid tumors [27]. Thus, the expression
is generally found in the order of follicular thyroid adenoma
> follicular thyroid carcinoma > papillary thyroid carcinoma
> medullary thyroid carcinoma > anaplastic thyroid carci-
noma [27, 37–39]. These studies use immunohistochemical
analysis of primary thyroid tissues, and low or no expression
of NKX2-1 is found in anaplastic thyroid carcinomas. Using
RT-PCR, NKX2-1 expression is reported in some anaplastic
thyroid carcinoma-derived cell lines [40, 41]. The latter
studies present diﬀerent results for the expression of NKX2-
1 within the same cell line, suggesting the controversial
nature of NKX2-1 expression. In order to explain the loss
of NKX2-1 expression in most of undiﬀerentiated thyroid
carcinomas and cell lines, epigenetic silencing of the NKX2-
1 gene through DNA hypermethylation and histone H3
modiﬁcation has been suggested [40]. Further studies are
required to obtain clear understanding of the relationships
in between expression of NKX2-1, diﬀerentiation status of
tissues and primary carcinomas versus cell lines, and the
mechanisms underlying the loss of NKX2-1 expression in
malignancy.
A genome-wide association study (GWAS) revealed the
predisposition of common variants on 9q22.33 and 14q13.3
to both papillary and follicular thyroid cancers. The gene
nearest to the 9q22.33 is FOXE1, and among the genes
located at the 14q13.3 locus is NKX2-1 [42], suggestingJournal of Thyroid Research 3
potential roles for these two thyroid-speciﬁc transcription
factors in thyroid cancers. A germline mutation of NKX2-1
gene leads to a mutant NKX2-1 protein (A339V) that has
impaired transactivation of thyroid-speciﬁc genes such as
thyroglobulin, thyrotropin receptor, and PAX8, while the ex-
pression is associated with the increased cell proliferation,
thyrotropin-independent growth, and enhanced activation
of survival signaling molecules such as Stat3and Aktas com-
pared to wild-type protein [43]. A population study dem-
onstrated that the NKX2-1 A339V mutant contributes to
predisposition of maltinodular goiter and/or papillary thy-
roid carcinomas and to the pathogenesis of papillary thyroid
carcinomas [43].
2.1.2.Nkx2-1Thyroid-SpeciﬁcConditionalKnockoutMouseas
a Model to Study Thyroid Carcinogenesis. Nkx2-1(ﬂ/ﬂ);TPO-
Cre thyroid-speciﬁc conditional knockout mouse provides
an animal model to study the role of NKX2-1 in adult thy-
roid, which circumvents the problem of immediate neo-
natal lethality of Nkx2-1-null mouse [44]. In the Nkx2-
1(ﬂ/ﬂ);TPO-Cre mouse, the recombination of Nkx2-1 ﬂoxed
geneoccurs atthe rateof ∼50%, resulting in Nkx2-1 thyroid-
speciﬁc conditional hypomorphic mouse [45]. These mice
exhibit either atrophic/degenerative thyroids with frequent
presence of adenomas and extremely high TSH levels, or
thyroids with reduced numbers of extremely dilated follicles
having more number of follicular cells than usual within a
follicle. The atrophic/degenerative thyroid mostly consists
of atrophic/degenerative follicles, in which many follicu-
lar cells frequently have lost NKX2-1 expression, suggest-
ing that the loss of NKX2-1 may be the cause of atrophic/
degenerative follicular cells [45]. These ﬁndings further
suggest that NKX2-1 is required for the maintenance of or-
dered architecture and function of the diﬀerentiated thyroid
[45].
In chemical carcinogenesis bioassays using the genotoxic
mutagen N-bis(2-hydroxypropyl)-nitrosamine (DHPN) fol-
lowed by sulfadimethoxine (SDM) as a promoter, the Nkx2-
1(ﬂ/ﬂ);TPO-Cre mice developed signiﬁcantly higher inci-
dence of adenomas as compared with wild-type or Nkx2-1-
heterozygous mice [46]. In contrast, with the non-genotoxic
carcinogen amitrole (3-amino-1,2,4-triazole), all three geno-
type groups of mice developed adenomas at similar inci-
dence. Surprisingly, no gene mutation was identiﬁed in any
adenoma-developed thyroids. The increased incidence of
adenomas in the Nkx2-1(ﬂ/ﬂ);TPO-Cre mice after genotoxic
carcinogenexposuremaybepartiallyexplainedbymorethan
a twofold higher cell proliferation rate found in these mouse
thyroids as compared to those of wild-type or Nkx2-1-
heterozygousmice.Theseresultsmaybeanalogoustohuman
exposure to genotoxic mutagens or radiation, which could
cause somatic mutation of NKX2-1 gene → inactivation of
NKX2-1 gene → degeneration of thyroid follicular cells →
increased cell proliferation → augmentation of the dam-
age occurred in DNA, and/or chromosomes by genotoxic
mutagensorradiation exposure, ultimately leading to cancer
[46].
2.2. FOXE1 and Cancer. The human FOEX1 gene is located
on chromosome 9q22.3 [47]. The loss of heterozygosity of
marker D9S180 from this chromosomal area is frequently
observedin squamouscell carcinomas ofskin, suggesting the
presence of tumor suppressor gene in this genomic region
[48]. The common variant rs965513 on 9q22.33 contributes
to an increased risk of papillary and follicular thyroid cancer
[42]. Further, a high incidence of FOXE1 gene promoter
methylation is found in cutaneous squamous cell carinomas
(SCC) [49], pancreatic cancers [50], and breast cancers [51].
FOXE1 protein has a polyalanine tract starting at the 13th
amino acid residue from the end of the forkhead domain,
which stretches from 12 to 17 residues with the 14 alanine
stretch at the highest frequency [47]. The less common
variant (allele 16) is associated with SCC, suggesting that the
more common variant (allele 14) may be protective against
developing SCC [52].
Similar to NKX2-1, FOXE1 expression is found in vari-
o u st h y r o i dc a n c e r s[ 38, 53]. The level of expression corre-
lates with their diﬀerentiation status as seen with NKX2-1,
and anaplastic thyroid carcinoma has very little expression
of FOXE1 [38, 53]. The candidate gene association study
revealed that the variant rs1867277 (−283G > A) located in
theFOXE1 5  UTRisassociated withpapillary thyroidcancer
susceptibility through recruitment of USF1/USF2 transcrip-
tionfactorstothe −283Aallele,whichaﬀectsgeneexpression
[54].FOXE1isrequiredforthyroidcellprecursorstomigrate
into the underlying mesenchyme from the thyroid bud [15,
55]. Although the exact mechanism for the enhanced tran-
scription of FOXE1 gene leading to increased susceptibility
to papillary thyroid cancer remains unknown, the enhanced
expression of FOXE1 in thyroid carcinomas could be related
to a motile advantage of malignant thyroid cells [54].
Radiation exposure causes papillary thyroid cancer as
revealed by various studies after the Chernobyl accident
[56]. Genome-wide association studies (GWAS) employing
Belarusian patients and control subjects demonstrated that
the variant rs965513 on 9q22.33 is signiﬁcantly associated
with the radiation-induced papillary thyroid cancer [57].
This variant was identiﬁed together with NKX2-1, as those
having the strongest rink to papillary and follicular thyroid
cancers [42]. Although Foxe1 thyroid conditional null mice
are currently not available, they would be a useful model to
understand the role of FOXE1 in the pathogenesis of thyroid
cancer.
2.3. PAX8
2.3.1. PAX8 and Cancer. PAX8 is a crucial transcription fac-
tor for organogenesis of the thyroid, kidney, and M¨ ullerian
system [8, 58]. PAX8 is expressed in normal as well as
neoplastic renal tissues, andin Wilms’ tumors[58,59].PAX8
is a useful marker for M¨ ullerian carcinomas [60]a n do v a r i a n
cancer [61, 62] and can be used to distinguish ovarian serous
tumorsfrommalignantmesothelioma [61–64]orfr omother
metastatic tumors such as breast and colon [63, 64].
PAX8 is expressed in various thyroid cancers; how-
ever, the pattern of expression is somewhat controversial;4 Journal of Thyroid Research
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Figure 1: Possible involvement of NKX2-1 and/or PAX8 in the maintenance and/or activity of stem cells of the thyroid. Transformation
of NKX2-1 and/or PAX8-expressing stem cells leads to thyroid cancer. Transformed NKX2-1 and/or PAX8-expressing stem cells self-renew
and proliferate to produce cancer. Upon becoming tumorigenic, most of transformed cells may lose NKX2-1 and/or PAX8 expression. FTC:
follicular thyroid carcinoma,PTC: papillary thyroid carcinoma, and MTC: medullary thyroid carcinoma.
onestudyshowedthatthenuclearPAX8stainingiscorrelated
with the thyroid diﬀerentiation phenotype as seen with
NKX2-1 and FOXE1 [27], while others demonstrated that
PAX8 is a useful marker for the diagnosis of anaplastic
carcinomas [38]. More studies are required to determine the
expression pattern and the role of PAX8 in thyroid cancers,
including the use of Pax8 thyroid-conditional null mice.
2.3.2. PAX8/PPARγ Fusion Oncogene in Thyroid Cancer. The
chromosomal translocation of the 2q13-qter region to 3p25
r e s u l t si na ni n - f r a m ef u s i o np r o t e i n( P P F P )b e t w e e nm o s t
of the coding sequence of PAX8 and the entire trans-
lated reading-frame of the nuclear receptor-family member
peroxisome proliferator-activated receptor gamma (PPARγ)
([65]r e v i e w e di n[ 66, 67]). The PPFP has several diﬀerent
PAX8 breakpoints while the PPARγ breakpoint seems to be
constant [65, 67, 68]. This fusion protein is more prevalently
expressed in follicular thyroid carcinomas (36%, reviewed
in [69]); however, follicular adenomas (11%), follicular
variant of papillary carcinoma (16%), and H¨ urthle cell
carcinoma (2%) also express PPFP [68–70]. PPFP has been
proposed to be an early follicular thyroid carcinoma-speciﬁc
oncogene [65, 71]. Several in vitro studies demonstrated
that PPFP has oncogenic activity such as increased cell cycle
transition, reduced apoptosis, and enhanced growth [71],
which is partly due to PPFP’s dominant negative activity
to suppress wild-type transcriptional activities of PPARγ
[65, 71, 72], the suggested tumor suppressor [73, 74]. PPFP
can also work as a dominant negative inhibitor of wild-type
PPARγ in vivo [75]. Further studies are required to establish
the mechanisms for the PPFP-mediated tumorigenesis.
3.Thyroid-SpeciﬁcTranscriptionFactors,
Cancer,and StemCells
N o r m a le m b ry o g e n e s i si sb e l i ev e dt os h a r em a n yo ft h es a m e
pathways as neoplasia, such as Wnt/β-catenin, Hedgehog,
and Notch pathways. These signaling pathways are also
involved in the maintenance and/or activity of stem cells,
while their dysregulation plays a role in tumorigenesis
(reviewed in [76–80]). It is increasingly recognized that
homeobox proteins including PAX proteins play a critical
role in stem cell maintenance [4, 81]. PAX3 or PAX7 is
essential for generating the cell pool of muscle progenitors
from which satellite cells derive [82]. Overexpression of
PAX3and7isfrequentlyfoundinpediatricsoft-tissue malig-
nant tumor rhabdomyosarcomas [83, 84]. PAX6 is essential
for maintenance of the multipotency of retinal progenitor
cells [85]. On the other hand, HOX genes are expressed in
hematopoietic cells in a stage- and lineage-speciﬁc manner,
and are implicated in leukemogenesis [81]; for instance,
HOXA10 is a critical regulator for haematopoietic stem
cells, and erythroid and megakaryocyte development [86],
while HOXA9isrequiredfor normal hematopoieticstem cell
function [87]. The involvements of other homeobox genesin
the maintenance of stem cells are described in various tissues
includingbrain[88]an dkidn ey[89].Inthe prostate, NKX3-
1 ,a n o t h e rm e m b e ro ft h eNKX gene family, is required for
stem cell maintenance [90]. The targeted deletion of Pten,Journal of Thyroid Research 5
a tumor suppressor gene in castration-resistant NKX3-1-
expressing cells, results in rapid carcinoma formation after
androgen-mediated regeneration [90].
The three transcription factors, NKX2-1, FOXE1, and
PAX8, are critical for normal embryogenesis and appear to
play a role in tumorigenesis in various tissues where they
are expressed, including the thyroid. By analogy to other
homeodomain/PAX proteins, it is likely that NKX2-1 and
PAX8 may be involved in the maintenance and/or activity
of stem cells in the thyroid, dysregulation of which may
lead to thyroid cancer (Figure 1). Currently, it is not clear
whether FOX transcription factors are involved in stem cell
maintenance/activity [3]. Knockout mouse studies demon-
strated that in the absence of NKX2-1, primordium cells
to both thyroid follicular and C cells disintegrate during
thyroid organogenesis [16, 91], while PAX8 is required for
the survival of follicular cells [17]. It would be interesting to
determine whether NKX2-1 and/or PAX8-expressing stem/
progenitor cells exist that can rapidly form cancers upon
targeted disruption of a tumor suppressor gene in cell pools,
similar to that seen with NKX3-1. In this regard, NKX2-1 in
lung cancers may be more analogous to this scenario since
NKX2-1 is a lineage-speciﬁc oncogene and is required for
survival of a subset of adenocarcinoma cells [33–35].
4.Conclusions
It appears that most transcription factors, if not all, that are
critical for developmental process are involved in the main-
tenance and/or activity of stem cells, whose dysregulation
results in cancers. Currently, it is entirely unknown whether
and/or how the thyroid-speciﬁc transcription factors NKX2-
1, FOXE1, and PAX8 are related to stem/progenitor cells
of the thyroid that may lead to cancer when dysregulated.
Identiﬁcation/characterization of thyroid stem/progenitor
cells, their relation to the expression of NKX2-1, FOXE1,
and/or PAX8, and more detailed characterization of various
thyroid cancers and/or cancer cells, particularly in relation
to the expression of these transcription factors, are urgently
required in order to better understand the roles of NKX2-1,
FOXE1, and PAX8 in thyroid cancer.
References
[1] C. Cillo, A. Faiella, M. Cantile, and E. Boncinelli, “Homeobox
genes and cancer,” Experimental Cell Research, vol. 248, no. 1,
pp. 1–9, 1999.
[ 2 ]F .D .N u n e s ,F .C .d eA l m e i d a ,R .T u c c i ,a n dS .C .d eS o u s a ,
“Homeoboxgenes:amolecularlinkbetween developmentand
cancer,”Pesquisa Odontologica Brasileira, vol.17,no.1,pp.94–
98, 2003.
[ 3 ] S .S .M y a t ta n dE .W .F .L a m ,“ T h ee m e r g i n gr o l e so ff o r k h e a d
box (Fox) proteins in cancer,” Nature Reviews Cancer,v o l .7 ,
no. 11, pp. 847–859, 2007.
[4] D. Lang, S. K. Powell, R. S. Plummer, K. P. Young, and B. A.
Ruggeri, “PAX genes: roles in development, pathophysiology,
and cancer,” Biochemical Pharmacology, vol. 73, no. 1, pp. 1–
14, 2007.
[ 5 ]S .G u a z z i ,M .P r i c e ,M .D eF e l i c e ,G .D a m a n t e ,M .G .M a t t e i ,
and R.Di Lauro, “Thyroid nuclear factor 1(TTF-1) containsa
homeodomain and displays a novel DNA binding speciﬁcity,”
EMBO Journal, vol. 9, no. 11, pp. 3631–3639, 1990.
[6] K. Mizuno, F. J. Gonzalez, and S. Kimura, “Thyroid-speciﬁc
enhancer-binding protein (T/EBP): cDNA cloning, func-
tional characterization, and structural identity with thyroid
transcription factor TTF-1,” Molecular and Cellular Biology,
vol. 11, no. 10, pp. 4927–4933, 1991.
[7] M. Zannini, V. Avantaggiato, E. Biﬀali et al., “TTF-2, a new
forkhead protein, shows a temporal expression in the devel-
oping thyroid which is consistent with a role in controlling
the onset of diﬀerentiation,” EMBO Journal, vol. 16, no. 11,
pp. 3185–3197, 1997.
[8] D. Plachov, K. Chowdhurry, C. Walther, D. Simon, J. L.
Guenet, and P. Gruss, “Pax8, a murine paired box gene
expressed in the developing excretory system and thyroid
gland,” Development, vol. 110, no. 2, pp. 643–651, 1990.
[9] F.Kikkawa,F.J.Gonzalez,andS.Kimura,“Characterizationof
athyroid-speciﬁcenhancerlocated5.5kilobasepairsupstream
of thehumanthyroid peroxidase gene,”Molecular and Cellular
Biology, vol. 10, no. 12, pp. 6216–6224, 1990.
[10] H. Francis-Lang, M. Zannini, M. De Felice, M. T. Berlingieri,
A. Fusco, and R. Di Lauro, “Multiple mechanisms of inter-
ference between transformationand diﬀerentiation in thyroid
cells,” Molecularand Cellular Biology,vol.12,no.12,pp.5793–
5800, 1992.
[11] M. Zannini, H. Francis-Lang, D. Plachov, and R. Di Lauro,
“Pax-8, a paired domain-containing protein, binds to a
sequence overlapping the recognition site of a homeodomain
and activates transcription from two thyroid-speciﬁc promot-
ers,” Molecular and Cellular Biology, vol. 12, no. 9, pp. 4230–
4241, 1992.
[12] M. Ohno, M. Zannini, O. Levy, N. Carrasco, and R. Di Lauro,
“The paired-domain transcription factor Pax8 binds to the
upstream enhancer of the rat sodium/iodide symporter gene
and participates in both thyroid-speciﬁc and cyclic-AMP-
dependent transcription,” Molecular and Cellular Biology,
vol. 19, no. 3, pp. 2051–2060, 1999.
[13] P. Santisteban, A. Acebron, M. Polycarpou-Schwarz, and R.
Di Lauro, “Insulin and insulin-like growth factor I regulate a
thyroid-speciﬁc nuclear protein that binds to the thyroglobu-
linpromoter,”MolecularEndocrinology,vol.6,no.8,pp.1310–
1317, 1992.
[14] G. Damante and R. Di Lauro, “Thyroid-speciﬁc gene expres-
sion,” Biochimica et Biophysica Acta, vol. 1218, no. 3, pp. 255–
266, 1994.
[15] M. De Felice, C. Ovitt, E. Biﬀali et al., “A mouse model
for hereditary thyroid dysgenesis and cleft palate,” Nature
Genetics,vol. 19, no. 4, pp. 395–398, 1998.
[16] S. Kimura, Y. Hara, T. Pineau et al., “The T/ebp null mouse:
thyroid-speciﬁc enhancer-binding protein is essential for the
organogenesis of the thyroid, lung, ventral forebrain, and
pituitary,” Genes and Development, vol. 10, no. 1, pp. 60–69,
1996.
[17] A. Mansouri, K. Chowdhury, and P. Gruss, “Follicular cells
of the thyroid gland require Pax8 gene function,” Nature
Genetics,vol. 19, no. 1, pp. 87–90, 1998.
[18] M. Felice and R. Lauro, “Murine models for the study of
thyroid gland development,” Endocrine Development, vol. 10,
pp. 1–14, 2007.
[19] N.Dathan,R.Parlato,A.Rosica,M.DeFelice,andR.DiLauro,
“Distribution ofthetitf2/foxe1geneproduct isconsistentwith
an important role in the development of foregut endoderm,6 Journal of Thyroid Research
palate, and hair,” Developmental Dynamics, vol. 224, no. 4,
pp. 450–456, 2002.
[20] J. Pohlenz, A. Dumitrescu, D. Zundel et al., “Partial deﬁciency
of thyroid transcription factor 1 produces predominantly
neurological defects in humans and mice,” Journal of Clinical
Investigation, vol. 109, no. 4, pp. 469–473, 2002.
[21] H. Krude, B. Sch¨ utz, H. Biebermann et al., “Choreoathetosis,
hypothyroidism, and pulmonary alterations due to human
NKX2-1 haploinsuﬃciency,” Journal of Clinical Investigation,
vol. 109, no. 4, pp. 475–480, 2002.
[22] M. A. A. P. Willemsen, G. J. Breedveld, S. Wouda et al.,
“Brain-Thyroid-Lungsyndrome:apatientwithaseveremulti-
system disorder due to a de novo mutation in the thyroid
transcription factor 1 gene,” European Journal of Pediatrics,
vol. 164, no. 1, pp. 28–30, 2005.
[23] R. J.Clifton-Bligh,J.M.Wentworth,P.Heinz et al.,“Mutation
of the gene encoding human TTF-2 associated with thyroid
agenesis, cleft palate and choanal atresia,” Nature Genetics,
vol. 19, no. 4, pp. 399–401, 1998.
[24] M. Castanet, S. M. Park, A. Smith et al., “A novel loss-of-
function mutation in TTF-2 is associated with congenital
hypothyroidism, thyroid agenesis and cleft palate,” Human
Molecular Genetics,vol. 11, no. 17, pp. 2051–2059, 2002.
[ 2 5 ]C .D iL o r e t o ,V .D iL a u r o ,F .P u g l i s i ,G .D a m a n t e ,D .
Fabbro,andC.A.Beltrami,“Immunocytochemicalexpression
of tissue speciﬁc transcription factor-1 in lung carcinoma,”
Journal of Clinical Pathology, vol. 50, no. 1, pp. 30–32, 1997.
[26] D. Tan, Q. Li, G. Deeb et al., “Thyroid transcription factor-
1 expression prevalence and its clinical implications in non-
small cell lung cancer: a high-throughput tissue microarray
and immunohistochemistrystudy,” Human Pathology,v o l .3 4 ,
no. 6, pp. 597–604, 2003.
[27] P. Zhang, H. Zuo, Y. Nakamura, M. Nakamura, T. Wakasa,
and K. Kakudo, “Immunohistochemical analysis of thyroid-
speciﬁc transcription factors in thyroid tumors,” Pathology
International, vol. 56, no. 5, pp. 240–245, 2006.
[28] M. Bongiovanni, P. M. Sadow, and W. C. Faquin, “Poorly dif-
ferentiated thyroid carcinoma: a cytologic-histologic review,”
Advances in Anatomic Pathology, vol. 16, no. 5, pp. 283–289,
2009.
[29] N. Nakamura, E. Miyagi, S. I. Murata, A. Kawaoi, and R.
Katoh,“Expressionofthyroidtranscriptionfactor-1innormal
andneoplasticlung tissues,”ModernPathology,vol.15, no.10,
pp. 1058–1067, 2002.
[30] J.Moldvay,M.Jackel,K.Bogosetal.,“TheroleofTTF-1 indif-
ferentiating primary and metastatic lung adenocarcinomas,”
Pathology and Oncology Research, vol. 10, no. 2, pp. 85–88,
2004.
[31] N.H.Myong,“Thyroid transcriptionfactor-1(TTF-1)expres-
sion in human lung carcinomas: its prognostic implication
and relationship with wxpressions of p53 and Ki-67 proteins,”
Journal of Korean Medical Science, vol. 18, no. 4, pp. 494–500,
2003.
[32] J.A. Barletta,S.Perner,A.J.Iafrateet al.,“Clinicalsigniﬁcance
of TTF-1 protein expression and TTF-1 gene ampliﬁcation
in lung adenocarcinoma,” Journal of Cellular and Molecular
Medicine, vol. 13, no. 8B, pp. 1977–1986, 2009.
[33] K. A. Kwei, Y. H. Kim, L. Girard et al., “Genomic proﬁling
identiﬁes TITF1 as a lineage-speciﬁc oncogene ampliﬁed in
lung cancer,” Oncogene, vol. 27, no. 25, pp. 3635–3640, 2008.
[34] H. Tanaka, K. Yanagisawa, K. Shinjo et al., “Lineage-speciﬁc
dependency of lung adenocarcinomas on the lung devel-
opment regulator TTF-1,” Cancer Research, vol. 67, no. 13,
pp. 6007–6011, 2007.
[ 3 5 ]B .A .W e i r ,M .S .W o o ,G .G e t ze ta l . ,“ C h a r a c t e r i z i n gt h e
cancer genome in lung adenocarcinoma,” Nature, vol. 450,
no. 7171, pp. 893–898, 2007.
[ 3 6 ]D .F a b b r o ,C .D iL o r e t o ,C .A .B e l t r a m i ,A .B e l ﬁ o r e ,R .
Di Lauro, and G. Damante, “Expression of thyroid-speciﬁc
transcription factors TTF-1 and PAX-8 in human thyroid
neoplasms,” Cancer Research, vol. 54, no. 17, pp. 4744–4749,
1994.
[37] N. G. Ord´ o˜ nez, “Thyroid transcription factor-1 is a marker of
lungandthyroid carcinomas,”Advancesinanatomicpathology,
vol. 7, no. 2, pp. 123–127, 2000.
[38] D. Nonaka,Y. Tang, L. Chiriboga, M. Rivera, and R. Ghossein,
“Diagnostic utility of thyroid transcription factors Pax8 and
TTF-2 (FoxE1) in thyroid epithelial neoplasms,” Modern
Pathology, vol. 21, no. 2, pp. 192–200, 2008.
[ 3 9 ]R .K a t o h ,E .M i y a g i ,N .N a k a m u r ae ta l . ,“ E x p r e s s i o no f
thyroid transcription factor-1 (TTF-1) in human C cells and
medullary thyroid carcinomas,” Human Pathology,v o l .3 1 ,
no. 3, pp. 386–393, 2000.
[40] T. Kondo, T. Nakazawa, D. Ma et al., “Epigenetic silencing of
TTF-1/NKX2-1 through DNA hypermethylation and histone
H3 modulation in thyroid carcinomas,” Laboratory Investiga-
tion, vol. 89, no. 7, pp. 791–799, 2009.
[41] W. C. G. Van Staveren, D. W. Sol´ ıs, L. Delys et al.,
“Human thyroidtumorcell linesderived fromdiﬀerent tumor
types present a common dediﬀerentiated phenotype,” Cancer
Research, vol. 67, no. 17, pp. 8113–8120, 2007.
[42] J. Gudmundsson, P. Sulem, D. F. Gudbjartsson et al., “Com-
mon variants on 9q22.33 and 14q13.3 predispose to thyroid
cancer in European populations,” Nature Genetics, vol. 41,
no. 4, pp. 460–464, 2009.
[ 4 3 ]E .S .W .N g a n ,B .H .H .L a n g ,T .L i ue ta l . ,“ Ag e r m l i n e
mutation (A339V) in thyroid transcription factor-1 (TITF-
1/NKX2.1) in patients with multinodular goiter and papillary
thyroid carcinoma,” Journal of the National Cancer Institute,
vol. 101, no. 3, pp. 162–175, 2009.
[44] T.Kusakabe,A.Kawaguchi,R.Kawaguchi,L.Feigenbaum,and
S. Kimura,“Thyrocyte-speciﬁc expression ofCre recombinase
in transgenic mice,” Genesis,vol. 39, no. 3, pp. 212–216, 2004.
[ 4 5 ]T .K u s a k a b e ,A .K a w a g u c h i ,N .H o s h i ,R .K a w a g u c h i ,S .
Hoshi, and S. Kimura, “Thyroid-speciﬁc enhancer-binding
protein/NKX2.1 is required for the maintenance of ordered
architecture andfunctionofthediﬀerentiated thyroid,” Molec-
ular Endocrinology, vol. 20, no. 8, pp. 1796–1809, 2006.
[46] S.Hoshi,N.Hoshi,M.Okamotoetal.,“RoleofNKX2-1inN-
bis(2-hydroxypropyl)-nitrosamine-induced thyroid adenoma
in mice,” Carcinogenesis, vol. 30, no. 9, pp. 1614–1619, 2009.
[ 4 7 ]P .E .M a c c h i a ,M .G .M a t t e i ,P .L a p i ,G .F e n z i ,a n dR .D i
Lauro, “Cloning,chromosomallocalizationand identiﬁcation
of polymorphisms in the human thyroid transcription factor
2 gene (TITF2),” Biochimie, vol. 81, no. 5, pp. 433–440, 1999.
[ 4 8 ]E .H o l m b e r g ,B .L .R o z e l l ,a n dR .T o f t g a r d ,“ D i ﬀerential allele
loss on chromosome 9q22.3 in human non-melanoma skin
cancer,” British Journal of Cancer, vol. 74, no. 2, pp. 246–250,
1996.
[49] I. Venza, M. Visalli, B. Tripodo et al., “FOXE1 is a target for
aberrant methylation in cutaneous squamous cell carcinoma,”
British Journal of Dermatology, vol. 162, no. 5, pp. 1093–1097,
2010.
[50] K. Brune, S. M. Hong, A. Li et al., “Genetic and epigenetic
alterations of familial pancreatic cancers,” Cancer Epidemiol-
ogy Biomarkers and Prevention, vol. 17, no. 12, pp. 3536–3542,
2008.Journal of Thyroid Research 7
[ 5 1 ]D .J .W e i s e n b e r g e r ,B .N .T r i n h ,M .C a m p a ne ta l . ,“ D N A
methylation analysis by digital bisulﬁte genomic sequencing
anddigitalMethyLight,”Nucleic AcidsResearch,vol.36,no.14,
pp. 4689–4698, 2008.
[ 5 2 ]I .V e n z a ,M .V i s a l l i ,B .T r i p o d o ,M .L e n t i n i ,D .T e t i ,a n d
M. Venza, “Investigation into FOXE1 genetic variations in
cutaneous squamous cell carcinoma,” British Journal of Der-
matology, vol. 162, no. 3, pp. 681–683, 2010.
[53] M. J. Sequeira, J. M. Morgan, D. Fuhrer, M. H. Wheeler, B.
Jasani, and M. Ludgate, “Thyroid transcription factor-2 gene
expression in benign and malignant thyroid lesions,” Thyroid,
vol. 11, no. 11, pp. 995–1001, 2001.
[54] I. Landa, S. Ruiz-Llorente, C. Montero-Conde et al., “The
variant rs1867277 in FOXE1 gene confers thyroid cancer
susceptibility through the recruitment of USF1/USF2 tran-
scription factors,” PLoS Genetics,v o l .5 ,n o .9 ,A r t i c l eI D
e1000637, 2009.
[55] R. Parlato, A. Rosica, A. Rodriguez-Mallon et al., “An inte-
grated regulatory network controlling survival and migration
in thyroid organogenesis,” Developmental Biology, vol. 276,
no. 2, pp. 464–475, 2004.
[56] D. Williams, “Cancer after nuclear fallout: lessons from the
Chernobyl accident,” Nature Reviews Cancer,v o l .2 ,n o .7 ,
pp. 543–549, 2002.
[57] M. Takahashi, V. A. Saenko, T. I. Rogounovitch et al., “The
FOXE1 locus is a major genetic determinant for radiation-
related thyroid carcinoma in Chernobyl,” Human Molecular
Genetics,vol. 19, no. 12, pp. 2516–2523, 2010.
[58] A. Poleev, H. Fickenscher, S. Mundlos et al., “PAX8, a human
paired box gene: Isolation and expression in developing
thyroid, kidney and Wilms’ tumors,” Development, vol. 116,
no. 3, pp. 611–623, 1992.
[ 5 9 ]G .X .T o n g ,W .M .Y u ,N .T .B e a u b i e re ta l . ,“ E x p r e s s i o no f
PAX8 in normal and neoplastic renal tissues: an immunohis-
tochemical study,” Modern Pathology, vol. 22, no. 9, pp. 1218–
1227, 2009.
[60] W. Wiseman, C. W. Michael, and M. H. Roh, “Diagnostic
utility of PAX8 and PAX2 immunohistochemistry in the
identiﬁcation of metastaticMullerian carcinoma in eﬀusions,”
Diagnostic Cytopathology. In press.
[61] A. R. Laury, J. L. Hornick, R. Perets et al., “PAX8 reliably
distinguishesovarianseroustumorsfrommalignantmesothe-
lioma,” American Journal of Surgical Pathology,v o l .3 4 ,n o .5 ,
pp. 627–635, 2010.
[62] D. Nonaka, L. Chiriboga, and R. A. Soslow, “Expression of
Pax8 as a useful marker in distinguishing ovarian carcinomas
from mammary carcinomas,” American Journal of Surgical
Pathology, vol. 32, no. 10, pp. 1566–1571, 2008.
[63] N. J. Bowen, S. Logani, E. B. Dickerson et al., “Emerging roles
for PAX8 in ovarian cancer and endosalpingeal development,”
Gynecologic Oncology, vol. 104, no. 2, pp. 331–337, 2007.
[ 6 4 ]M .F u j i w a r a ,J .T a u b e ,M .S h a r m a ,T .H .M c C a l m o n t ,a n dJ .
Kim, “PAX8 discriminates ovarian metastases from adnexal
tumors and other cutaneous metastases,”Journal of Cutaneous
Pathology, vol. 37, no. 9, pp. 938–943, 2010.
[65] T.G.Kroll,P.Sarraf,L.Pecciarinietal.,“PAX8-PPARγ1f u si on
in oncogene human thyroid carcinoma,” Science, vol. 289,
no. 5483, pp. 1357–1360, 2000.
[66] M. Sobrinho-Sim˜ oes, V. M´ aximo, A. S. Rocha et al.,
“Intragenic mutations in thyroid cancer,” Endocrinology and
Metabolism Clinics of North America, vol. 37, no. 2, pp. 333–
362, 2008.
[67] N. L. Eberhardt, S. K. G. Grebe, B. McIver, and H. V.
Reddi, “The role of the PAX8/PPARγ fusion oncogene in
the pathogenesis of follicular thyroid cancer,” Molecular and
Cellular Endocrinology, vol. 321, no. 1, pp. 50–56, 2010.
[68] A.R.Marques,C.Espadinha,A.L.Catarinoetal.,“Expression
of PAX8-PPARγ1 rearrangements in both follicular thyroid
carcinomas and adenomas,” Journal of Clinical Endocrinology
and Metabolism, vol. 87, no. 8, pp. 3947–3952, 2002.
[69] K.A.Placzkowski,H.V .R eddi,S.K.G.G r ebe,N.L.Eberhar dt,
and B. McIver, “The role of the PAX8/PPARγ fusiononcogene
in thyroid cancer,” PPAR Research, vol. 2008, Article ID
672829, 10 pages, 2008.
[ 7 0 ]L .C h e u n g ,M .M e s s i n a ,A .G i l le ta l . ,“ D e t e c t i o no ft h e
PAX8-PPARγ fusion oncogene in both follicular thyroid
carcinomas and adenomas,” Journal of Clinical Endocrinology
and Metabolism, vol. 88, no. 1, pp. 354–357, 2003.
[71] J. G. Powell, X. Wang, B. L. Allard et al., “The PAX8/PPARγ
fusion oncoprotein transforms immortalized human thyro-
cytes through a mechanism probably involving wild-type
PPARγ inhibition,” Oncogene, vol. 23, no. 20, pp. 3634–3641,
2004.
[ 7 2 ]A .Y . M .A u ,C .M c B r i d e ,K .G .W i l h e l mJ r .e ta l . ,“ P A X 8 -
peroxisome proliferator-activated receptor γ (PPARγ)d i s -
rupts normal PAX8 or PPARγ transcriptional function and
stimulates follicular thyroid cell growth,” Endocrinology,
vol. 147, no. 1, pp. 367–376, 2006.
[73] D. Bonoﬁglio, E. Cione, H. Qi et al., “Combined low doses of
PPARγ andRXRligandstriggeranintrinsicapoptoticpathway
in human breast cancer cells,” American Journal of Pathology,
vol. 175, no. 3, pp. 1270–1280, 2009.
[ 7 4 ]J .Y u ,B O .S h e n ,E .S .H .C h ue ta l . ,“ I n h i b i t o r yr o l eo f
peroxisome proliferator-activated receptor gamma in hepato-
carcinogenesis in mice andin vitro,” Hepatology,v ol.51,no .6,
pp. 2008–2019, 2010.
[75] Y. Yin, H. Yuan, X. Zeng, L. Kopelovich, and R. I. Glazer,
“Inhibition of peroxisome proliferator-activated receptor γ
increases estrogen receptor-dependent tumor speciﬁcation,”
Cancer Research, vol. 69, no. 2, pp. 687–694, 2009.
[76] M. Mimeault and S. K. Batra, “Frequent deregulations in
the hedgehog signaling network and cross-talks with the
epidermal growth factor receptor pathway involved in cancer
progression and targeted therapies,” Pharmacological Reviews,
vol. 62, no. 3, pp. 497–524, 2010.
[77] M. W. Saif and E. Chu, “Biology of colorectal cancer,” Cancer
Journal, vol. 16, no. 3, pp. 196–201, 2010.
[ 7 8 ]L .Y i n ,O .C .V e l a z q u e z ,a n dZ .J .L i u ,“ N o t c hs i g n a l i n g :
E m e r g i n gm o l e c u l a rt a r g e t sf o rc a n c e rt h e r a p y , ”Biochemical
Pharmacology, vol. 80, no. 5, pp. 690–701, 2010.
[79] P. Wend, J. D. Holland, U. Ziebold, and W. Birchmeier, “Wnt
signaling in stem and cancer stem cells,” Seminars in Cell and
Developmental Biology, vol. 21, no. 8, pp. 855–863, 2010.
[80] P. Heretsch, L. Tzagkaroulaki, and A. Giannis, “Modulators
of the hedgehog signaling pathway,” Bioorganic and Medicinal
Chemistry, vol. 18, no. 18, pp. 6613–6624, 2010.
[81] S. Samuel and H. Naora, “Homeobox gene expression in
cancer: Insights from developmental regulation and deregu-
lation,” European Journal of Cancer, vol. 41, no. 16, pp. 2428–
2437, 2005.
[ 8 2 ]F .R e l a i x ,D .R o c a n c o u r t ,A .M a n s o u r i ,a n dM .B u c k i n g -
ham, “A Pax3/Pax7-dependent population of skeletal muscle
progenitor cells,” Nature, vol. 435, no. 7044, pp. 948–953,
2005.8 Journal of Thyroid Research
[83] M. Bernasconi, A. Remppis, W. J. Fredericks, F. J. Rauscher,
a n dB .W .S c h ¨ afer, “Induction of apoptosis in rhabdomyosar-
coma cells through down-regulation of PAX proteins,” Pro-
ceedings of theNational Academyof Sciencesof theUnited States
of America, vol. 93, no. 23, pp. 13164–13169, 1996.
[84] N. Tiﬃn, R. D. Williams, J. Shipley, and K. Pritchard-Jones,
“PAX7 expression in embryonal rhabdomyosarcoma suggests
an origin in muscle satellite cells,” British Journal of Cancer,
vol. 89, no. 2, pp. 327–332, 2003.
[ 8 5 ]T .M a r q u a r d t ,R .A s h e r y - P a d a n ,N .A n d r e j e w s k i ,R .S c a r d i g l i ,
F. Guillemot, and P. Gruss, “Pax6 is required for the multi-
potent state of retinal progenitor cells,” Cell, vol. 105, no. 1,
pp. 43–55, 2001.
[86] M. Magnusson, A. C. M. Brun, N. Miyake et al., “HOXA10
is a critical regulator for hematopoietic stem cells and
erythroid/megakaryocyte development,”Blood,vol.109,no.9,
pp. 3687–3696, 2007.
[ 8 7 ]H .J .L a w r e n c e ,J .C h r i s t e n s e n ,S .F o n ge ta l . ,“ L o s so fe x p r e s -
sion of the Hoxa-9 homeobox gene impairs the proliferation
and repopulating ability of hematopoietic stem cells,” Blood,
vol. 106, no. 12, pp. 3988–3994, 2005.
[ 8 8 ]A .L a v a d o ,O .V .L a g u t i n ,L .M .L .C h o w ,S .J .B a k e r ,a n d
G. Oliver, “Prox1 Is required for granule cell maturation and
intermediate progenitor maintenance during brain neurogen-
esis,” PLoS Biology, vol. 8, no. 8, pp. 43–44, 2010.
[ 8 9 ]M .S e l f ,O .V .L a g u t i n ,B .B o w l i n ge ta l . ,“ S i x 2i sr e q u i r e df o r
suppression of nephrogenesis and progenitor renewal in the
developing kidney,” EMBO Journal, vol. 25, no. 21, pp. 5214–
5228, 2006.
[ 9 0 ]X I .W a n g ,M .K r u i t h o f - d eJ u l i o ,K .D .E c o n o m i d e se ta l . ,“ A
luminal epithelial stem cell that is a cell of origin for prostate
cancer,” Nature, vol. 461, no. 7263, pp. 495–500, 2009.
[ 9 1 ] T .K u s a k a b e ,N .H o s h i ,a n dS .K i m u r a ,“ O r i g i no ft h eu l t i m o -
branchial body cysts: T/ebp/Nkx2.1 expression is required for
development and fusion of the ultimobranchial body to the
thyroid,” Developmental Dynamics, vol. 235, no. 5, pp. 1300–
1309, 2006.